Tag: Diabetes: Type II
ACP: Recommendations Developed for Newer Type 2 Diabetes Medications
Strong recommendation given for addition of SGLT-2 or GLP-1 agonist to metformin and lifestyle modifications
ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes
Larger reductions seen in heart failure-related symptoms and physical limitations for patients with HFpEF, type 2 diabetes
EHR-Based Algorithm Does Not Cut Hospitalization in Kidney Dysfunction Triad
No reduction seen in hospitalization at one year with use of EHR-based algorithm and practice facilitators in primary care
Short Sleep Duration Linked to Increased Risk for Developing T2D
Association between habitual short sleep duration and increased risk for T2D persisted for individuals following healthy diet
Markers of Systemic Inflammation May Aid Diabetes Risk Prediction
Findings seen for high-sensitivity C-reactive protein, monocyte-to-high-density lipoprotein ratio
FDA Says Yogurt Makers Can Make ‘Qualified’ Claims About T2D Prevention
'Qualified health claim' does not meet the more rigorous 'significant scientific agreement' standard
Type 2 Diabetes Remission Maintained After RYGB Despite Weight Regain
Overall rate of continued diabetes remission higher for those undergoing RYGB versus sleeve gastrectomy
Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Kidney Stone Risk
Findings seen compared with glucagon-like peptide 1 receptor agonists or dipeptidyl peptidase 4 inhibitors
Exercise Intensity, Duration Can Affect CKD Risk in Obesity, Type 2 Diabetes
Inverse link seen for total MVPA, MVPA accumulated in bouts of ≥10 minutes with progression to CKD in overweight/obese adults with T2D
GLP1 Agonists Reduce Major Adverse Liver Outcomes in Chronic Liver Disease
For patients with chronic liver disease and type 2 diabetes, GLP1 agonist initiators associated with lower risk for major adverse liver outcomes
